



Antigens in Cancer

Guest Editor:

Prof. Dr. Moonsoo Jin

Department of Surgery, Weill
Cornell Medicine, New York, NY
10065, USA

Deadline for manuscript
submissions:

closed (20 August 2023)

Message from the Guest Editor

In this special issue, we are particularly interested in papers that report on the identification and/or characterization of novel antigens in cancer and different agents that target these novel antigens. Moreover, papers leading to the development of specific methodologies aiming at the better screening/identification/quantification of cancer antigens would be of great interest. Reviews that summarize current knowledge gained from the preclinical and clinical studies of TCR- and CAR-T cells against cancer would be particularly useful. Potential topics include, but are not limited to:

- Identification or prioritization of novel cancer antigens
- Methodologies for the detection of cancer antigens
- Next-generation or fine-tuning of TCR or CAR constructs to overcome immune suppression or avoid toxicity
- Novel cancer-antigen-specific small molecules or peptides as carriers of cytotoxic drugs or radioisotopes
- Novel antibody designs and formats for improved pharmacokinetics or conjugation with cytotoxic drugs or radioisotopes.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)